What is the primary use for the medication Lucentis?

Lucentis, also known by its generic name ranibizumab, is primarily used to treat exudative age-related macular degeneration (AMD). This condition involves the growth of abnormal blood vessels underneath the retina, leading to leakage of fluid and blood that can severely impair vision. Lucentis is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), a protein that promotes the growth of these abnormal vessels. By blocking VEGF, Lucentis helps reduce vascular permeability and improve visual acuity in patients suffering from this form of AMD.

Other options like the treatment of glaucoma, management of dry eye syndrome, or correction of refractive errors are not applicable for Lucentis. Glaucoma treatments focus on reducing intraocular pressure, dry eye syndrome management involves lubricants or anti-inflammatory medications, and refractive errors are typically corrected with glasses, contact lenses, or surgical interventions. Hence, the specific mechanism and application of Lucentis directly relate to its primary use in treating exudative age-related macular degeneration.